Exenatide Reduces Graft Injury in a Rat Transplantation Model Using Kidneys Donated after Cardiac Death

Area of Science:

• Nephrology
• Transplantation Immunology
• Pharmacology

Background:

• Exenatide, a glucagon-like peptide-1 receptor agonist, is known for type 2 diabetes therapy and neuroprotection.
• Kidney grafts procured after cardiac death (DCD) are susceptible to ischemia-reperfusion (I/R) injury and apoptosis.
• Reducing I/R injury is crucial for improving outcomes in kidney transplantation (KTx).

Purpose of the Study:

• To investigate the protective effects of exenatide on DCD kidney grafts.
• To evaluate exenatide's ability to inhibit apoptosis and reduce I/R injury in a rat KTx model.
• To assess the impact of exenatide on graft function, survival, and inflammatory responses post-KTx.

Main Methods:

• A rat syngeneic KTx model using DCD kidney grafts was established.
• Exenatide was administered to donor animals prior to graft procurement.
• Apoptosis markers, graft function, survival rates, histological changes, and inflammatory mediator expression were analyzed post-KTx.

Main Results:

• Exenatide pretreatment significantly decreased caspase pathway activation and apoptosis markers (TUNEL, cleaved caspase-3, PARP) in kidney grafts.
• Post-KTx, exenatide treatment led to improved renal function, reduced acute tubular necrosis, macrophage infiltration, and interstitial fibrosis.
• Exenatide downregulated the expression of key inflammatory mediators (TNF-α, IL-6, IL-1β, ICAM-1) in the transplanted kidneys.

Conclusions:

• Exenatide demonstrates significant protective effects against I/R injury in DCD kidney grafts.
• Pretreatment with exenatide improves graft viability, function, and recipient survival following KTx.
• Exenatide's anti-apoptotic and anti-inflammatory properties make it a promising therapeutic agent for DCD kidney transplantation.